Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Aktis Oncology, Inc.NASDAQ: AKTS
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue of $18.96M in Q1 FY2026
Q1 FY2026 deferred revenue was $18.96M.
Context
- Deferred revenue amounted to 3.3% of total assets at the end of Q1 FY2026.
- Deferred revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 18.66M USD
- Year-over-year change
- +101.2%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.66M | +101.2% |
| FY2024 | 2024-12-31 | 9.28M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 deferred revenue of $18.96M is the 2nd highest of the 6 companies compared; the peer median is $572K.
- Deferred revenue amounts to 3.3% of total assets for AKTS, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $67.99M | +335.3% | +3.0% | 31.2% | |
| Mar 2026 | $18.96M | — | — | 3.3% | |
| Mar 2026 | $2.8M | -77.7% | -47.5% | 0.4% | |
| Mar 2026 | $572K | — | -57.8% | 0.1% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AKTS) | $572K | +128.8% | -47.5% | 0.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.